Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoalbuminemia in patients receiving cisplatin: correlation between liver platinum and decrease in serum albumin.

A A Nanji, N Z Mikhael, D J Stewart

    Oncology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Use of dietary saturated fatty acids and vitamin E in the treatment of alcoholic liver disease.

    Asia Pacific journal of clinical nutrition·2014
    Same author

    Glycosylated hemoglobins: a review.

    Canadian family physician Medecin de famille canadien·2011
    Same author

    Are routine measurements of serum chloride and total carbon dioxide levels worth doing?

    Canadian Medical Association journal·2010
    Same author

    Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).

    Histology and histopathology·2009
    Same author

    Role of the fractalkine receptor CX3CR1 polymorphisms V249I and T280M as risk factors for early-onset coronary artery disease in patients with no classic risk factors.

    Scandinavian journal of clinical and laboratory investigation·2008
    Same author

    Inhibitors of inducible nitric oxide (NO) synthase are more effective than an NO donor in reducing carbon-tetrachloride induced acute liver injury.

    Histology and histopathology·2006

    Cisplatin chemotherapy can decrease serum albumin levels in advanced cancer patients. Higher liver platinum concentrations correlate with greater albumin decline, suggesting potential cisplatin-induced liver toxicity.

    Area of Science:

    • Oncology
    • Pharmacology
    • Hepatology

    Background:

    • Cisplatin is a widely used chemotherapy agent for various advanced malignancies.
    • Serum albumin levels are a key indicator of nutritional status and overall health in cancer patients.
    • Potential organ toxicities of cisplatin require ongoing investigation.

    Purpose of the Study:

    • To investigate the relationship between cisplatin administration and changes in serum albumin concentrations.
    • To explore the correlation between liver platinum levels and serum albumin decline in patients with advanced malignancy.

    Main Methods:

    • Prospective evaluation of 15 patients with advanced malignancy receiving cisplatin.
    • Serial measurements of serum albumin concentrations throughout treatment.

    Related Experiment Videos

  • Correlation analysis between serum albumin changes and autopsy liver platinum levels.

    • Main Results:

    • A significant correlation was observed between the decrease in serum albumin and liver platinum levels at autopsy (r = 0.46, p < 0.05).
    • Patients with liver platinum concentrations > 1.5 µg/g showed a significantly greater decrease in serum albumin (1.0 ± 0.45 g/dL) compared to those with levels ≤ 1.5 µg/g (0.16 ± 0.23 g/dL; p < 0.02).

    Conclusions:

    • Cisplatin treatment is associated with a decrease in serum albumin levels in patients with advanced malignancy.
    • The observed decrease in serum albumin may be attributed to a hepatotoxic effect of cisplatin, indicated by the correlation with liver platinum accumulation.